IR情報

2020/06/23~2020/11/18

IR情報&株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2020
11/181,7201,7781,7201,765+2.14%133,500255億4184万+0.17%
11/171,7791,7941,7261,728-3.03%247,100250億640万-2.54%
11/161,8021,8131,7541,782-0.22%103,800257億8785万-0.17%
11/131,7801,7971,7521,786+0.56%104,800258億4574万-0.56%
11/121,7961,8041,7541,776-1.11%126,800257億102万-1.82%
11/111,7431,8021,7361,796+5.03%219,000259億9045万-1.37%
11/101,7251,7551,6941,710-2.17%169,100247億4592万-6.81%
11/091,6891,7481,6731,748+2.64%299,900252億9583万-5.51%
11/0615:00 営業外費用及び特別損失の計上に関するお知らせ
11/0615:00 2020年12月期第3四半期決算短信〔日本基準〕(非連結)
11/0615:00 報告セグメントの廃止に関するお知らせ
11/061,7051,7391,6891,703-1.96%172,000246億4462万-8.64%
11/051,7421,7681,7111,737+0.12%125,800251億3664万-7.56%
11/041,6661,7401,6661,735+4.83%156,600251億770万-8.39%
11/021,6481,6791,6311,655+1.41%198,700239億5000万-13.12%
10/301,7161,7441,6201,632-5.72%280,300236億1716万-15.04%
10/291,6851,7331,6601,731+1.05%210,500250億4982万-10.68%
10/281,7301,7701,7031,713-2.28%121,200247億8933万-12.42%
10/271,7101,7611,6851,753+0.69%140,200253億6818万-11.2%
10/261,7141,7621,7081,741+0.64%138,300251億9453万-12.51%
10/231,7071,7431,6431,730+0.93%350,400250億3534万-13.8%
10/221,7501,7501,6941,714-2.72%328,900248億380万-15.23%
10/211,7371,7961,7371,7620%168,500254億9843万-13.46%
10/201,7991,8131,7411,762-3.56%301,500254億9843万-14.01%
10/191,7851,8361,7361,827+2.41%274,900264億3906万-11.27%
10/161,9751,9821,7701,784-9.85%992,400258億1679万-13.69%
10/151,9982,0121,9611,979-1.44%333,300286億3870万-4.76%
10/142,0172,0352,0032,008-0.84%185,300290億5837万-3.37%
10/132,0402,0402,0002,025-1.03%217,800293億438万-2.6%
10/122,0382,0622,0212,046+0.05%161,100296億827万-1.68%
10/092,1002,1142,0312,045-2.67%285,500295億9380万-1.73%
10/082,1012,1262,0762,101+0.77%171,500304億420万+0.96%
10/072,1302,1342,0772,085-2.89%213,200301億7266万+0.29%
10/062,1012,1472,0752,147+2.73%194,700310億6988万+3.42%
10/052,1102,1262,0772,090-0.1%188,500302億4501万+0.77%
10/022,1042,1392,0552,092+0.19%302,000302億7395万+0.63%
09/302,0942,1142,0632,088-0.24%133,800302億1607万+0.34%
09/292,0202,0942,0202,093+3.56%150,600302億8843万+0.34%
09/282,0442,0732,0042,021-1.61%214,000292億4649万-3.39%
09/252,0412,0842,0322,054-0.58%159,300297億2405万-2.19%
09/242,1542,1552,0472,066-4.75%357,300298億9770万-2.04%
09/232,1232,1722,1122,169+0.18%186,800313億8824万+2.55%
09/1815:00 特別損失の発生に関するお知らせ
09/182,1502,1652,1262,165+0.23%149,900313億3036万+2.36%
09/172,1822,1842,1122,160-0.6%302,100312億5800万+2.03%
09/162,0902,1732,0782,173+3.97%300,600314億4613万+2.45%
09/152,0762,0992,0522,090+0.67%124,700302億4501万-1.46%
09/142,0882,1012,0572,076+0.39%181,800300億4241万-2.26%
09/112,0412,0721,9912,068+2.83%238,900299億2664万-2.64%
09/102,0452,0611,9982,011-1.42%159,800291億178万-5.28%
09/092,0002,0461,9982,040-0.34%150,300295億2145万-4.27%
09/081,9942,0551,9712,047+2.66%249,400296億2275万-4.08%
09/072,0302,0411,9611,994-1.43%304,900288億5577万-6.65%
09/042,0272,0612,0112,023-2.27%281,500292億7543万-5.33%
09/032,0562,1132,0352,070+0.93%248,100299億5559万-3.27%
09/022,0802,1182,0312,051-0.49%224,400296億8063万-4.2%
09/012,0532,0782,0292,061+0.54%163,100298億2534万-3.92%
08/312,0202,0942,0202,050+2.09%219,500296億6616万-4.65%
08/2818:30 取締役の人事に関するお知らせ
08/282,0902,0981,9902,008-4.29%545,400290億5837万-7.12%
08/272,2002,2122,0872,098-4.46%395,400303億6078万-3.54%
08/262,1902,2332,1632,196+1.48%274,400317億7897万+0.6%
08/252,1862,2052,1412,164-1.32%280,800313億1589万-1.1%
08/242,2632,2732,1582,193-3.09%409,400317億924万-0.18%
08/2115:00 譲渡制限付株式報酬としての自己株式の処分に関するお知らせ
08/212,2292,2802,2052,263+2.35%291,300327億2139万+2.35%
08/202,2822,2902,1852,211-3.15%394,800319億6951万-0.45%
08/192,2152,2832,1832,283+3.16%324,100330億1058万+2.15%
08/182,1602,2242,1302,213+2.5%272,300319億9843万-1.51%
08/172,2462,2712,1402,159-3.18%421,600312億1762万-4.6%
08/142,2632,3292,2072,230-1.33%547,100322億4423万-2.66%
08/132,1862,2832,1632,260+4.48%519,600326億7801万-2.46%
08/122,1512,2002,1182,163-0.32%444,200312億7546万-7.6%
08/112,1102,2152,0532,170+5.03%647,200313億7668万-8.79%
08/0715:00 2020年12月期第2四半期決算短信〔日本基準〕(非連結)
08/0715:00 営業外費用の計上に関するお知らせ
08/0715:00 頭頸部がんを対象としたテロメライシンのPhase2医師主導治験契約に関するお知らせ
08/072,0192,0852,0102,066+1.22%440,600298億7291万-14.31%
08/0615:00 COVID-19(新型コロナウイルス感染症)治療薬の開発方針について
08/062,2262,2352,0332,041-7.69%951,000295億1143万-16.86%
08/052,1312,2352,1132,211+3.66%631,900319億6951万-11.56%
08/042,0862,1722,0762,133+2.25%573,200308億4168万-16.16%
08/032,0152,0962,0012,086+3.01%419,000301億6209万-19.49%
07/312,0762,1412,0152,025-3.89%755,500292億8008万-23.38%
07/302,0762,1322,0182,107+1.01%708,600304億6574万-21.96%
07/292,1542,1722,0632,086-3.2%570,200301億6209万-24.12%
07/282,1752,2312,1152,155-1.19%562,000311億5979万-23.39%
07/272,3262,3302,1762,181-6.95%848,200315億3573万-23.39%
07/222,3302,3602,2452,344+0.3%491,900338億9259万-18.04%
07/212,3032,3652,2822,337+1.56%590,100337億6100万-18.6%
07/202,3082,3502,2302,301-0.73%763,400332億4093万-19.83%
07/172,3902,4312,2802,318-3.38%994,600334億8652万-18.78%
07/162,5482,5502,3962,399-5.1%1,018,400346億5667万-15.68%
07/152,5422,5682,4652,528+0.2%669,500362億3711万-10.8%
07/1415:00 譲渡制限付株式報酬としての新株式の払込完了に関するお知らせ
07/142,5602,6662,4812,523-1.06%1,064,200361億6543万-10.69%
07/132,5832,5922,4762,550-1.28%753,900365億5246万-9.25%
07/102,6202,7072,5252,583-1.41%1,175,400370億2549万-7.42%
07/092,8552,8812,6112,620-8.55%1,747,400375億5586万-5.28%
07/082,8862,9392,7932,865-0.24%1,036,900410億6776万+4.41%
07/072,7622,9062,7602,872+0.35%1,259,900411億6810万+6.49%
07/063,0253,0402,8062,862-7.97%1,713,200410億2476万+8%
07/032,9113,1602,9113,110+4.71%806,600445億7967万+19.52%
07/023,2053,2352,9222,970-6.46%1,404,900425億7287万+16.79%
07/0115:00 肝細胞がんPhase1企業治験の完了に関するお知らせ
07/013,1903,2753,1203,175+0.16%576,900455億1140万+27.46%
06/303,3503,3652,9003,170-4.23%1,157,500454億3973万+30.29%
06/293,2353,3703,2253,310+0.15%680,200474億4653万+39.72%
06/263,4303,4303,3003,305-2.36%756,600473億7486万+43.63%
06/2513:30 譲渡制限付株式報酬としての新株式発行に関するお知らせ
06/253,3653,5303,2503,385-1.46%2,301,300485億2160万+51.45%
06/243,3353,6903,2553,435+3.15%3,722,700492億3832万+58.73%
06/233,7503,8203,3053,330-10%5,680,200477億3321万+59.33%
06/1913:00 COVID-19(新型コロナウイルス感染症)治療薬の開発着手について